Cargando…

Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development

Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD’s impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachman, Shelby L., Blankenship, Jennifer M., Busa, Michael, Serviente, Corinna, Lyden, Kate, Clay, Ieuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578291/
https://www.ncbi.nlm.nih.gov/pubmed/37545234
http://dx.doi.org/10.3233/JAD-230152
_version_ 1785121490582110208
author Bachman, Shelby L.
Blankenship, Jennifer M.
Busa, Michael
Serviente, Corinna
Lyden, Kate
Clay, Ieuan
author_facet Bachman, Shelby L.
Blankenship, Jennifer M.
Busa, Michael
Serviente, Corinna
Lyden, Kate
Clay, Ieuan
author_sort Bachman, Shelby L.
collection PubMed
description Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD’s impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established clinical outcome assessments fail to capture subtle clinical changes, entail high burden for patients and their caregivers, and ineffectively address the aspects of health deemed important by patients and their caregivers. AD progression is associated with widespread changes in physical behavior that have impacts on the ability to function independently, which is a meaningful aspect of health for patients with AD and important for diagnosis. However, established assessments of functional independence remain underutilized in AD clinical trials and are limited by subjective biases and ceiling effects. Digital measures of real-world physical behavior assessed passively, continuously, and remotely using digital health technologies have the potential to address some of these limitations and to capture aspects of functional independence in patients with AD. In particular, measures of real-world gait, physical activity, and life-space mobility captured with wearable sensors may offer value. Additional research is needed to understand the validity, feasibility, and acceptability of these measures in AD clinical research.
format Online
Article
Text
id pubmed-10578291
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-105782912023-10-17 Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development Bachman, Shelby L. Blankenship, Jennifer M. Busa, Michael Serviente, Corinna Lyden, Kate Clay, Ieuan J Alzheimers Dis Review Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD’s impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established clinical outcome assessments fail to capture subtle clinical changes, entail high burden for patients and their caregivers, and ineffectively address the aspects of health deemed important by patients and their caregivers. AD progression is associated with widespread changes in physical behavior that have impacts on the ability to function independently, which is a meaningful aspect of health for patients with AD and important for diagnosis. However, established assessments of functional independence remain underutilized in AD clinical trials and are limited by subjective biases and ceiling effects. Digital measures of real-world physical behavior assessed passively, continuously, and remotely using digital health technologies have the potential to address some of these limitations and to capture aspects of functional independence in patients with AD. In particular, measures of real-world gait, physical activity, and life-space mobility captured with wearable sensors may offer value. Additional research is needed to understand the validity, feasibility, and acceptability of these measures in AD clinical research. IOS Press 2023-09-12 /pmc/articles/PMC10578291/ /pubmed/37545234 http://dx.doi.org/10.3233/JAD-230152 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Bachman, Shelby L.
Blankenship, Jennifer M.
Busa, Michael
Serviente, Corinna
Lyden, Kate
Clay, Ieuan
Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
title Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
title_full Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
title_fullStr Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
title_full_unstemmed Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
title_short Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
title_sort capturing measures that matter: the potential value of digital measures of physical behavior for alzheimer’s disease drug development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578291/
https://www.ncbi.nlm.nih.gov/pubmed/37545234
http://dx.doi.org/10.3233/JAD-230152
work_keys_str_mv AT bachmanshelbyl capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment
AT blankenshipjenniferm capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment
AT busamichael capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment
AT servientecorinna capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment
AT lydenkate capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment
AT clayieuan capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment